Answers are grounded in this paper and cite their sources.
• Evidence pertaining to temocillin in non-urinary AmpC infections is limited. • This study reports on real-life use of temocillin in digestive and respiratory infections. • Clinical cure was achieved in all patients at Day 28. • No relapse or infection-related death occurred. • Temocillin may in selected cases be considered as a carbapenem-sparing option. Infections due to AmpC-producing Enterobacterales represent an increasing therapeutic challenge. Third-generation cephalosporins may select resistant mutants, inducing clinicians to use cefepime or carbapenems and thereby contributing to carbapenem resistance. While temocillin is a narrow-spectrum beta-lactam stable against AmpC enzymes, evidence of its impact in non-urinary tract infections remains limited. We conducted a retrospective study of adult patients treated with temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales between 2016 and 2021. Clinical, microbiological and therapeutic data were collected. The primary outcome was treatment failure within twenty-eight days. Six patients were included, with a median age of sixty-one years; three required intensive care. Infection sites were digestive or respiratory. All patients had achieved clinical cure by day twenty-eight, without recurrence, infection-related mortality, or adverse events. Having led to favorable outcomes, temocillin may represent a carbapenem-sparing option when in vitro susceptibility is confirmed. These findings call for further evaluation in larger prospective clinical studies.
No takes yet. Share an insight, caveat, or question.
Mamona-Kilu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: